NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes

28m ago🟢 Mild Positive
Share𝕏inf

Cohealyx cut graft readiness time in complex wounds, showing strong healing and safety data.

What the company is saying

AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH) is highlighting the complete six-month results from its Cohealyx I study, positioning Cohealyx as a clinically superior option for preparing full-thickness wounds for grafting. The company frames its narrative around statistically significant acceleration of wound readiness for grafting, with a mean time of 13.6 days versus a 28-day benchmark, and a median of 11 days. AVITA emphasizes high surgeon satisfaction, improved scar outcomes, and the absence of device-related adverse events through 26 weeks. The announcement features commentary from Dr. Derek Bell, Professor of Plastic Surgery and Kessler Burn Director at the University of Rochester Medical Center, who serves as a medical advisor and underscores the product’s value in complex cases. CEO Cary Vance reinforces the message that these results provide clinicians with robust evidence for choosing Cohealyx in burn and trauma wound care. The tone is confident, focusing on clinical achievement and safety, and the company is explicit about the study being company-funded and post-market, aiming to support further clinical adoption.

What the data suggests

The Cohealyx I study enrolled 40 patients with full-thickness wounds, 57.5% of whom had burns and 42.5% non-burn wounds. A high-risk population was targeted, with 77.5% having at least one risk factor for impaired healing and 65% classified as ASA III or IV, indicating severe systemic disease. The study met its primary endpoint, with a mean time to graft readiness of 13.6 days, significantly faster than the 28-day lower bound of the comparator's 95% confidence interval (p<0.001), and a median time of 11 days. 72% of patients were ready for grafting within two weeks. At eight weeks post-grafting, 88% of assessed patients achieved wound healing, and only 2.5% required regrafting. Scar quality improved, with Vancouver Scar Scale scores dropping from 5.2 at week 12 to 3.5 at week 26. No Cohealyx-related adverse events were reported through 26 weeks. Microscopic analysis confirmed tissue integration, vascularization, and balanced inflammation. The study was funded by AVITA Medical and conducted post-market, with results presented at a major burn association conference. The data are robust for clinical endpoints but do not address commercial adoption, revenue, or cost-effectiveness.

Analysis

The announcement provides detailed, realised clinical results from the Cohealyx I study, including six-month follow-up data and clear statistical comparisons to established performance goals. The majority of claims are factual and supported by quantitative data, such as time to graft readiness, healing rates, and scar improvement. Only a small fraction of statements are forward-looking, describing the intended use and design rationale of the product, rather than making aspirational commercial or financial projections. There is no evidence of exaggerated tone or narrative inflation; the language is proportionate to the clinical outcomes reported. The only capital outlay mentioned is the funding of the study, with no indication of a large, uncertain investment or long-dated benefit timeline. However, the absence of any profitability or financial metrics means the signal cannot be rated above weak_positive, as investors cannot assess the commercial impact or sustainability of these clinical results.

Risk flags

  • ●The absence of commercial adoption or revenue data means the financial impact of these clinical results remains unquantified, limiting investor ability to assess near-term value creation.
  • ●The study population was relatively small (40 patients), and while high-risk, multicenter, and post-market, broader generalizability to routine clinical practice or larger populations is not yet established.
  • ●Although no device-related adverse events were reported through 26 weeks, longer-term safety or rare complications cannot be fully excluded based on the current data set.

Bottom line

AVITA Medical’s Cohealyx I study demonstrates that the product can prepare complex wounds for grafting significantly faster than established dermal matrices, with 72% of patients ready within two weeks and strong healing and scar outcomes through six months. The safety profile is favorable, with no device-related adverse events and only one patient requiring regrafting. These results strengthen the clinical case for Cohealyx, especially in high-risk patients, but the announcement does not provide any data on sales, market penetration, or economic impact. Investors should recognize that while the clinical evidence is robust, the pathway to commercial value is unaddressed in this update. The most important takeaway is that Cohealyx has met and exceeded clinical performance benchmarks in a challenging patient population, but further disclosures on adoption and financial outcomes are needed to gauge broader investment relevance.

Announcement summary

(NASDAQ: RCEL, ASX: AVH) AVITA Medical, Inc. announced complete results, including six-month follow-up, from its Cohealyx I study in patients with full-thickness wounds. The Cohealyx I study was a prospective, single-arm, post-market, multicenter study evaluating clinical outcomes of Cohealyx in 40 patients with full-thickness wounds following surgical excision. Burn wounds accounted for 57.5% of patients, while non-burn wounds accounted for 42.5%. Most patients (77.5%) had at least one risk factor for impaired healing, and 65% had severe systemic disease, classified as American Society of Anesthesiologists (ASA) physical status III or IV. The study met its primary endpoint, demonstrating significantly earlier readiness for skin grafting against the lower bound of a performance goal derived from published studies of other dermal matrices (p<0.001). The mean time to graft readiness was 13.6 days, compared with the 28-day performance goal, and the median time was 11 days. 72% of patients were ready for grafting within two weeks. At 8 weeks after grafting, 88% of patients assessed achieved healing of the treated wound, with continued progression to week 26. One patient (2.5%) required regrafting. Mean Vancouver Scar Scale scores improved from 5.2 at week 12 to 3.5 at week 26, where lower scores indicate less scar abnormality on the 0–13 scale. No Cohealyx related adverse events were reported during follow-up through 26 weeks after grafting. Microscopic examination of wound samples taken immediately before grafting showed that cells had entered the matrix, with a balanced inflammatory response, revascularization, and new tissue and collagen formation. The study used a performance goal based on a meta-analysis of published studies of other dermal matrices, which reported a mean time to grafting of 33.2 days, with a 95% confidence interval of 28.0 to 38.4 days. Statistical testing compared Cohealyx’s mean time to graft readiness with the lower bound of that interval, 28 days. Follow-up extended through 26 weeks after grafting, and the number of patients assessed varied by visit and endpoint. AVITA Medical funded the study. Dr. Derek Bell, Professor of Plastic Surgery and Kessler Burn Director at the University of Rochester Medical Center, served as a medical advisor to the company. Cary Vance is the Chief Executive Officer of AVITA Medical. Cohealyx is a collagen-based dermal matrix designed to support vascularization and prepare the wound bed for closure, intended for use in staged surgical procedures for acute full-thickness wounds. AVITA Medical’s broader portfolio includes RECELL and PermeaDerm. In the U.S., AVITA Medical holds exclusive rights to market, sell, and distribute Cohealyx, and to manufacture, market, sell, and distribute PermeaDerm. Internationally, RECELL is approved for skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO are CE-marked in Europe, have TGA certification in Australia, are listed with Medsafe in New Zealand, and RECELL is PMDA-approved in Japan.

Disagree with this article?

Ctrl + Enter to submit